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ABSTRACT
Introduction. Traditional evaluation of meningitis includes cerebro-
spinal fluid (CSF) culture and gram stain to pinpoint specific causal 
organisms. The BioFire® FilmArray® Meningitis/Encephalitis (ME) 
Panel has been implemented as a more timely evaluation method. 
This study sought to assess if the BioFire® ME Panel was associated 
with a decreased length of stay or decreased antimicrobial duration 
when used in the diagnosis of meningitis or encephalitis.
Methods.xA case, historical-control, chart review was performed on 
patients admitted to a regional medical center with CSF pleocytosis 
during  Cohort 1 (the year prior to BioFire® ME Panel implementation) 
and Cohort 2 (the year after BioFire® ME Panel implementation). 
Length of hospital stay, duration of antimicrobials, and BioFire® ME 
Panel result were gathered and analyzed.
Results. Average length of stay for both cohorts was about four 
hospital days. Approximately three-fourths of all patients received 
antibiotic/antiviral treatment with an average of three days duration. 
No significant differences were observed between groups. The mean 
(median) duration of antimicrobials in the year prior to and after 
the BioFire® ME Panel implementation was 3.6 (3) and 3.1 (2) days, 
respectively (p = 0.835). The mean (median) length of stay in the year 
prior to and after the BioFire® ME Panel implementation was 5.8 (4) 
and 5.4 (4) days, respectively (p = 0.941). Among the patients admit-
ted after the implementation of the BioFire® ME Panel, 4.3 % (n = 
2) had a positive bacterial result, 38.3% (n = 18) had a positive viral 
result, and 57.4% (n = 27) had a negative result. Of the 27 negative 
results, 77.8% (n = 21) were treated with antimicrobial medication.
Conclusions. This study suggested there is no difference between 
length of stay or antimicrobial duration in presumed meningitis cases 
assessed with traditional methods as compared to the BioFire® ME 
Panel. Kans J Med 2019;12(1):1-3.
INTRODUCTION
  Meningitis, defined as inflammation of the leptomeninges sur-
rounding the brain and spinal cord, has a worldwide incidence of 
about 1.2 million cases yearly.1 Crucial in the evaluation of meningitis 
cases is the prompt retrieval of cerebrospinal fluid (CSF) via lumbar 
puncture to assess for organismal etiology of the infection. Evaluation 
of CSF includes culture and gram stain to pinpoint specific organisms 
causing infections. These traditional methods often take several days 
to render results leading to prolonged use of broad spectrum antimi-
crobials. Use of meningitis/encephalitis polymerase chain reaction 
(PCR) panels have been implemented as a supplemental organism 
identification method.
The BioFire® FilmArray® Meningitis/Encephalitis PCR Panel 
(BioFire® ME Panel) is a multiplex PCR assay that is able to iden-
tify 14 viral, bacterial, and fungal organisms that cause meningitis 
or encephalitis with high diagnostic specificity and sensitivity.2 This 
diagnostic test was similar in price per patient when compared to a 
classic  CSF culture.3 With the BioFire® ME Panel providing a reliable 
diagnosis and cost effective method, the question arises about the 
effect the test has on course of treatment. This study assessed if the 
utilization of the BioFire® ME Panel was associated with a decrease 
in length of hospital stay and duration of antimicrobials when used in 
the diagnosis of meningitis or encephalitis.
METHODS
 Design.  A case, historical-control study design was used to iden-
tify medical records for patients who were hospitalized for suspected 
meningitis. Cohort 1 included patients who were diagnosed using a 
cerebrospinal fluid culture and gram stain (CSF culture only: Year 
1) during a hospital stay from August 7, 2015 through 2016. Cohort 2 
included patients from August 8, 2016 through 2017 who were diag-
nosed with the BioFire® ME Panel: Year 2.
 Participants.  Patients were included if they were 18 years or older 
and had white blood cell counts greater than or equal to 10. Patients 
were excluded if younger than 18 years of age, received antimicro-
bial therapy for reasons other than meningitis/encephalitis, taking 
chemotherapy, diagnosed with sepsis, HIV/AIDS, or other non-infec-
tious neurological disorder or condition (Figure 1).
 Data Extraction. The OneChart EHR system was utilized to 
perform a chart review on patients who qualified for inclusion in 
the study at a regional medical center. Data regarding length of hos-
pital stay in days (LOS), treatment with or without antimicrobials, 
which included duration use in days, and results from the BioFire® 
ME Panel (positive-viral, positive-bacterial, negative, not used) 
were gathered and entered into a REDCap™ database. REDCap is a 
secure, web-based application that was developed specifically around 
HIPAA-security guidelines to house patient data. All information 
transmission is encrypted to protect the identity of study partici-
pants.4 
 Analysis Plan.  Data were summarized by cohort: CSF culture: 
Year 1 versus BioFire® ME Panel: Year 2. Continuous variables 
included LOS and duration of antimicrobials in days. To determine 
appropriate statistical tests, data were evaluated for normality with 
the Kolmogorov-Smirnov test. As data were highly skewed, and 
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assumption. Therefore, these were summarized with medians and 
interquartile ranges (IQR). Cohort differences were evaluated with 
Mann-Whitney U tests. Categorical data included one dichotomous 
variable, treatment with or without antimicrobials, which were 
summarized by cohort using frequencies and percentages. Pearson 
Chi-square test was conducted to compare cohorts by treatment. 
Where data were sparse, exact testing procedures were utilized. Sig-
nificant group differences were based on test results of p < 0.05. All 
statistical analyses were conducted with IBM SPSS Statistics, Version 
23.
Figure 1. Inclusion and exclusion criteria. 
RESULTS
 During the two study periods, a total of 342 patients were reported 
with white blood cell counts greater than or equal to 10: 164 were in 
Cohort 1 (CSF culture: Year 1), while 178 were in Cohort 2 (BioFire® 
ME Panel: Year 2; Figure 1). For Cohort 1,  50 patients met all inclu-
sion criteria, with 114 patients being excluded. Of the 178 patients in 
Cohort 2, 47 met inclusion criteria with 131 patients excluded. Thus, 
a total of 97 patients were included in the analysis. 
Table 1 illustrates group comparisons for hospital stay, antimicro-
bial treatment, and antibiotic/antiviral duration, along with results for 
BioFire® ME Panel: Year 2. Groups were similar across all attributes 
and no significant differences were observed. Average length of stay 
was about four hospital days per group; approximately three-fourths 
of all patients received antibiotic/antiviral treatment with an average 
of three days duration. Among the 47 patients who were evaluated 
with the BioFire® ME Panel, 4.3% (n =  2) had a positive bacterial 
result, 38.3% (n = 18) had a positive viral result, and 57.4% (n =  27) 
had a negative result.  Among the 27 participants with a negative panel 
result, 77.8% (n =  21) were treated with antimicrobial medication for 
an average of four days (IQR: 2.0, 5.0).
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Table 1. CSF culture versus BioFire® ME Panel: hospital stay, 
antiviral duration, antimicrobial treatment.
Length of 
Hospital 
Stay (days)
Treated with
Antimicrobials
Antibiotic/
Antiviral 
(days)
Diagnostic 
Instrument n
Median 
(IQR) n (%) Median (IQR)
Cohort 1: CSF 
Culture only 50 4 (3.0, 7.0) 36 (72.0) 3 (2.5, 5.0)
Cohort 2: Bio-
Fire® ME Panel 47 4 (2.0, 7.0) 36 (76.6) 3 (2.0, 5.0)
p-value 0.935* 0.648** 0.571*
BioFire® ME 
Panel results
   Positive      
   Bacterial 2 6 (3.0, 9.0) 2 (100.0) 6 (3.0, 9.0)
   Positive 
   Viral 18 2 (2.0, 5.0) 13 (72.2) 2 (2.0, 4.0)
   Negative 27 6 (3.0, 10.0) 21 (77.8) 4 (2.0, 5.0)
IQR: Interquartile ranges
*Mann-Whitney U exact test
**Pearson chi-square exact test
Next, cohorts were compared by antimicrobial status. No signifi-
cant difference was observed in hospital days between Cohort 1 and 
2, regardless of treatment status. For those who were administered 
antimicrobials, Cohort 1 median LOS was 5.0 (IQR: 3.0, 7.0), while 
Cohort 2 LOS was 4.5 (IQR: 3.0, 9.0); p = 0.759. For those who did 
not receive antimicrobials, Cohort 1 median LOS was 2.5 days (IQR: 
1.0, 4.25), and for Cohort 2 it was 1.0 days (IQR: 1.0, 5.0); p = 0.851. 
Although, sample size was small for each cohort without treatment, 
n  = 14 and 11, respectively. 
Further, test results showed a significant difference occurred for 
length of hospital stay between those who received antimicrobial 
treatment compared to those who did not: median hospital days with 
antimicrobials was 5.0 (IQR: 3.0, 7.5) versus without LOS was 2.0 
(IQR: 1.0, 4.0); p < 0.001. Because data were sparse, a generalized 
linear model using the Gamma distribution and log link function (to 
account for the skewed LOS data) was conducted with a bootstrap 
sample of 5,000 (to account for data sparseness). Results showed 
that antimicrobial treatment was not a significant predictor of LOS; 
p = 0.223. Thus, the significant difference found above may be due to 
the wide variability of hospital days among participants, along with 
the small sample size.
DISCUSSION
The purpose of the current study was to determine if the diagnos-
tic utilization of the BioFire® ME Panel decreased hospital length of 
stay and antimicrobial duration. This study suggested that utilizing 
this panel has little impact on the number of hospital days or treat-
ment duration. However, data were sparse, and statistical results were 
inconsistent regarding length of stay with and without treatment.
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These findings may be due to several factors. For example, unin-
tentional inclusion of patients without meningitis or encephalitis 
(conditions would otherwise explain an elevated WBC), insufficient 
sample size, patient characteristics, such as sex, age, or other comor-
bidities that might have shed light on these results, and utilization 
of antimicrobials by clinicians despite negative BioFire® ME Panel 
results. A larger scale study with similar parameters may reveal sig-
nificant differences between these groups. 
Of the 27 negative BioFire® ME Panel results, 21 (77.8%) were 
continued on antimicrobial therapy despite the result. Chang et al.5 
found similar results when assessing the BioFire® ME Panel’s role in 
antibiotic stewardship. The current study suggested that clinicians 
proceed with antimicrobial treatment regardless of a negative result. 
This may be due to clinicians’ concerns with risk of mortality without 
treatment or other healthcare-related concerns.6
CONCLUSIONS
The BioFire® ME Panel as a diagnostic tool has the potential to 
target antimicrobial treatment in a timely and cost effective manner. 
However, evidence of its potential to decrease the use of unnecessary 
antimicrobials is lacking. Future investigations into antimicrobial 
treatment in lieu of a negative result on the BioFire® ME Panel are 
warranted. With altered management of meningitis and encepha-
litis cases worked up with BioFire® ME Panels and a similar study 
of larger caliber, the potential may exist to shorten antimicrobial 
duration and length of hospital stay for patients hospitalized with 
meningitis/encephalitis.
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